<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35576353</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-233X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>139</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Obstetrics and gynecology</Title>
          <ISOAbbreviation>Obstet Gynecol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hormonal Intrauterine Devices and Acne.</ArticleTitle>
        <Pagination>
          <StartPage>919</StartPage>
          <EndPage>921</EndPage>
          <MedlinePgn>919-921</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/AOG.0000000000004765</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pakey</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Boston University School of Medicine and the Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; and the Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nassim</LastName>
            <ForeName>Janelle S</ForeName>
            <Initials>JS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reynolds</LastName>
            <ForeName>Rachel V</ForeName>
            <Initials>RV</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Obstet Gynecol</MedlineTA>
        <NlmUniqueID>0401101</NlmUniqueID>
        <ISSNLinking>0029-7844</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003278">Contraceptives, Oral, Hormonal</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000152" MajorTopicYN="Y">Acne Vulgaris</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003278" MajorTopicYN="N">Contraceptives, Oral, Hormonal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007434" MajorTopicYN="Y">Intrauterine Devices</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007436" MajorTopicYN="Y">Intrauterine Devices, Medicated</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>14</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35576353</ArticleId>
        <ArticleId IdType="doi">10.1097/AOG.0000000000004765</ArticleId>
        <ArticleId IdType="pii">00006250-202205000-00026</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Daniels K, Abma JC. Current contraceptive status among women aged 15–49: United States, 2017–2019. NCHS Data Brief, no 388. National Center for Health Statistics; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Teal SB, Turok D, Chen B, Kimble T, Olariu AI, Creinin MD, et al. Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system. Obstet Gynecol 2019;133:63–70. doi: 10.1097/aog.0000000000003034</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/aog.0000000000003034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M, et al. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002;99:608–13. doi: 10.1097/00006250-200204000-00019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00006250-200204000-00019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kokandi A. Evaluation of acne quality of life and clinical severity in acne female adults. Dermatol Res Pract 2010;2010;410809. doi: 10.1155/2010/410809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2010/410809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dréno B, Thiboutot D, Layton AM, Berson D, Perez M, Kang S, et al. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol 2014; 29:1096–106. doi: 10.1111/jdv.12757</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jdv.12757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lullo JJ, Ethington E, Arshanapalli A, Adams W, Graziano S, Tung R. Incidence of androgenic dermatologic side effects following placement of a levonorgestrel intrauterine device for menorrhagia: a survey-based study. J Am Acad Dermatol 2018;79:364–5. doi: 10.1016/j.jaad.2017.12.051</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2017.12.051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubuisson JB, Mugnier E. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years. Contraception 2002;66:121–8. doi: 10.1016/s0010-7824(02)00329-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0010-7824(02)00329-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbieri JS, Mitra N, Margolis D, Harper CC, Mostaghimi A, Abuabara K, et al. Influence of contraception class on incidence and severity of acne vulgaris. Obstet Gynecol 2020;135:1306–12. doi: 10.1097/aog.0000000000003880</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/aog.0000000000003880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaenglein A, Pathy A, Schlosser BJ, Stern M, Boyer KM, Bhushan R, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:945–73. doi: 10.1016/j.jaad.2015.12.037</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2015.12.037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol 2020;156:621–30. doi: 10.1001/jamadermatol.2020.0465</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2020.0465</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35576353</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-233X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>139</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Obstetrics and gynecology</Title>
          <ISOAbbreviation>Obstet Gynecol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hormonal Intrauterine Devices and Acne.</ArticleTitle>
        <Pagination>
          <StartPage>919</StartPage>
          <EndPage>921</EndPage>
          <MedlinePgn>919-921</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/AOG.0000000000004765</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pakey</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Boston University School of Medicine and the Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; and the Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nassim</LastName>
            <ForeName>Janelle S</ForeName>
            <Initials>JS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reynolds</LastName>
            <ForeName>Rachel V</ForeName>
            <Initials>RV</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Obstet Gynecol</MedlineTA>
        <NlmUniqueID>0401101</NlmUniqueID>
        <ISSNLinking>0029-7844</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003278">Contraceptives, Oral, Hormonal</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000152" MajorTopicYN="Y">Acne Vulgaris</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003278" MajorTopicYN="N">Contraceptives, Oral, Hormonal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007434" MajorTopicYN="Y">Intrauterine Devices</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007436" MajorTopicYN="Y">Intrauterine Devices, Medicated</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>14</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35576353</ArticleId>
        <ArticleId IdType="doi">10.1097/AOG.0000000000004765</ArticleId>
        <ArticleId IdType="pii">00006250-202205000-00026</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Daniels K, Abma JC. Current contraceptive status among women aged 15–49: United States, 2017–2019. NCHS Data Brief, no 388. National Center for Health Statistics; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Teal SB, Turok D, Chen B, Kimble T, Olariu AI, Creinin MD, et al. Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system. Obstet Gynecol 2019;133:63–70. doi: 10.1097/aog.0000000000003034</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/aog.0000000000003034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M, et al. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002;99:608–13. doi: 10.1097/00006250-200204000-00019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00006250-200204000-00019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kokandi A. Evaluation of acne quality of life and clinical severity in acne female adults. Dermatol Res Pract 2010;2010;410809. doi: 10.1155/2010/410809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2010/410809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dréno B, Thiboutot D, Layton AM, Berson D, Perez M, Kang S, et al. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol 2014; 29:1096–106. doi: 10.1111/jdv.12757</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jdv.12757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lullo JJ, Ethington E, Arshanapalli A, Adams W, Graziano S, Tung R. Incidence of androgenic dermatologic side effects following placement of a levonorgestrel intrauterine device for menorrhagia: a survey-based study. J Am Acad Dermatol 2018;79:364–5. doi: 10.1016/j.jaad.2017.12.051</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2017.12.051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubuisson JB, Mugnier E. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years. Contraception 2002;66:121–8. doi: 10.1016/s0010-7824(02)00329-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0010-7824(02)00329-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbieri JS, Mitra N, Margolis D, Harper CC, Mostaghimi A, Abuabara K, et al. Influence of contraception class on incidence and severity of acne vulgaris. Obstet Gynecol 2020;135:1306–12. doi: 10.1097/aog.0000000000003880</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/aog.0000000000003880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaenglein A, Pathy A, Schlosser BJ, Stern M, Boyer KM, Bhushan R, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:945–73. doi: 10.1016/j.jaad.2015.12.037</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2015.12.037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol 2020;156:621–30. doi: 10.1001/jamadermatol.2020.0465</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2020.0465</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
